

ASX Announcement
9 February 2021

Regeneus to be granted new key patent to target pain in Japan

Regeneus Ltd (ASX: RGS) (Regeneus or the Company), a clinical-stage regenerative medicine company, announced today that the Japanese Patent Office has decided to grant the Company a new key patent, covering the use of its lead stem cell technology Progenza™ to treat pain, through to 2032.

Regeneus already holds granted patents for the use of Progenza™ to treat inflammatory conditions, such as osteoarthritis. This new patent expands Regeneus' intellectual property portfolio into the \$85.5Bⁱ global pain market.

Pursuant to the terms of the Company's licence and collaboration agreement with Kyocera Corporation (Kyocera), to commercialise Progenza™ OA in Japan, Kyocera also has first rights to develop Progenza™ for additional indications for the Japanese market. The patent to be granted covering the use of Progenza™ to treat pain is included within this agreement.

Regeneus Chief Executive Officer, Karolis Rosickas, said the patent supports the Company's plan to explore additional licences for Progenza™ to treat other indications.

"Regeneus continues to explore all opportunities to address the gap in the projected \$85.5B global pain management drugs market with our disease modifying stem cell technologies.

"This new key patent will support the Company's efforts by helping us secure new licences for Progenza™ to treat other indications relating to pain."

-ENDS-

About Regeneus

Regeneus Ltd (ASX:RGS) is a Sydney-based clinical-stage regenerative medicine company using stem cell technologies to develop a portfolio of novel cell-based therapies. The regenerative therapies seek to address unmet medical needs in human health markets, focusing on neuropathic pain, including osteoarthritis and various skin conditions, with its platform technologies Progenza™ and Sygenus. Visit www.regeneus.com.au for more information.

Authorisation & Additional information

This announcement was authorised by the Board of Directors of Regeneus Ltd

Investor and Media Contact

WE Communications
T: 02 9237 2805
E: WE-AURegeneus@we-worldwide.com

ⁱ Allied Market Research, *Pain Management Drugs Market by Drug Class, (NSAIDs, Anesthetics, Anticonvulsant, Anti-Migraine Drug, Antidepressant Drugs, Opioids, and Non-Narcotic Analgesics) and Indication (Arthritic Pain, Neuropathic Pain, Cancer Pain, Chronic Pain, Post-Operative Pain, Migraine, and Fibromyalgia): Global Opportunity Analysis and Industry Forecast, 2019–2027 (2020)*

For personal use only